Article ; Online: Coronavirus disease 2019 and coagulopathy: other prothrombotic coagulation factors.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
2021 Volume 32, Issue 1, Page(s) 44–49
Abstract: There is an increasing evidence supporting the existence of coagulopathy in coronavirus disease ... coagulation parameters in these patients that could be involved in a hypercoagulate state and ... patients (15%) had a thrombotic event and all had several abnormal coagulation parameters related ...
| Abstract | There is an increasing evidence supporting the existence of coagulopathy in coronavirus disease 2019 (COVID-19) patients. Most of reports are mainly focused on d-dimer. Our objective is to describe coagulation parameters in these patients that could be involved in a hypercoagulate state and to test platelet function to see if there are short closure times. We analyzed coagulation samples from 80 patients admitted with COVID-19 in our hospital. We also tested platelet function by closure times in a small subgroup of patients. Most of samples had increased d-dimer (96.2%) (median of d-dimer: 1158 ng/ml FEU), increased fibrinogen (75.2%) (median: 5.23 g/l), increased factor VIII (86%) (median: 264.8 U/dl), decreased protein S (22.5% of women, 62.5% of men) (median: 62.8 and 68.5 U/dl, respectively), decreased protein C (7.6%) (median: 100 U/dl), decreased factor XII (25.3%) (median: 90.3 U/dl) and decreased antithrombin activity (21%) (median: 86 U/dl). International normalized ratio was higher than normal in 24 patients (30%) (median: 1.13). The activated partial thromboplastin time ratio was below the normal range in nine patients (11.2%) and above normal in three (3.75%) (median: 0.93). The closure times were short in the 20% and 40% of samples of collagen and ADP and collagen and epinephrine, respectively. Twelve of the 80 patients (15%) had a thrombotic event and all had several abnormal coagulation parameters related with increased thrombotic risk. The results of this study support a hypercoagulability state in COVID-19 patients and it may help to explain the microvascular thrombosis caused by the inflammatory response. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Anticoagulants/pharmacology ; Anticoagulants/therapeutic use ; Biomarkers/blood ; Blood Coagulation Disorders/etiology ; COVID-19/complications ; Female ; Fibrin Fibrinogen Degradation Products/adverse effects ; Humans ; Male ; Middle Aged ; Pandemics ; Platelet Function Tests/methods ; SARS-CoV-2 |
| Chemical Substances | Anticoagulants ; Biomarkers ; Fibrin Fibrinogen Degradation Products ; fibrin fragment D |
| Language | English |
| Publishing date | 2021-01-05 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 1033551-1 |
| ISSN | 1473-5733 ; 0957-5235 |
| ISSN (online) | 1473-5733 |
| ISSN | 0957-5235 |
| DOI | 10.1097/MBC.0000000000000996 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2920: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.